Kairos Pharma Ltd.

In the news! Fierce Biotech covered Kairos' IPO. Read the article below.

"Kairos goes public with $6M IPO to fund trials of lead drug.

With a trio of hitting the on Friday, it was easy to miss a smaller-scale public debut from another clinical-stage drug developer on the other side of the European Society of Medical annual meeting this weekend.

Unlike last week’s nine-figure offerings, Kairos Pharma’s IPO brought in a more modest $6.2 million yesterday. The Los Angeles-based biotech—whose stock listed on the under the ticker “KAPA” Sept. 16—sold 1.55 million shares at $4 apiece."

Full article: https://loom.ly/nuhjFg0

NYSE: KAPA

Interested in keeping up with Kairos Pharma?

Stay up to date with our latest news, events, and more here: https://kairospharma.com/

"This achievement pushes the envelope of immune therapies designed to target Tcells against devastating cancers," Kairos Chief Scientific Officer Neil Bhowmick, Ph.D.

Read more: https://www.prnewswire.com/news-releases/kairos-pharma-receives-fda-approval-of-investigational-new-drug-ind-application-for-its-phase-1-clinical-trial-of-kros-201-for-the-treatment-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html

Our recent patent covers the method of treating fibrosis and certain forms of cancer, the composition of matter, and administering a therapy using KROS-401, a cyclic peptide inhibitor of the IL-4 and IL-13 cytokine receptor complex.

https://www.prnewswire.com/news-releases/kairos-pharma-receives-fda-approval-of-investigational-new-drug-ind-application-for-its-phase-1-clinical-trial-of-kros-201-for-the-treatment-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html

Kairos Pharma is a clinical-stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.

Find out how we seek to transform the way cancer is treated: https://kairospharma.com/about/

ICYMI Kairos gets FDA clearance to begin Phase I trial of therapy. The trial of KROS 201 in recurrent glioblastoma patients will be initiated in .

Read more via GlobalData here: https://www.clinicaltrialsarena.com/news/kairos-trial-glioblastoma-therapy/

Kairos gets FDA clearance to begin Phase I trial of glioblastoma therapy The US FDA has granted clearance to Kairos Pharma’s IND application to commence Phase I trial of its KROS 201 for treating glioblastoma.

"This first-in-man Phase 1 clinical trial will activate T cells against the cancer stem cells at the root of glioblastoma," commented Kairos CEO John Yu, M.D.

Read more: https://www.prnewswire.com/news-releases/kairos-pharma-receives-fda-approval-of-investigational-new-drug-ind-application-for-its-phase-1-clinical-trial-of-kros-201-for-the-treatment-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html

Our new patent covers the method of treating fibrosis and certain forms of cancer, the composition of matter, and administering a therapy using KROS-401.

Read more: https://www.prnewswire.com/news-releases/kairos-pharma-receives-fda-approval-of-investigational-new-drug-ind-application-for-its-phase-1-clinical-trial-of-kros-201-for-the-treatment-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html

Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system.

Find out how we are developing small molecules that target these central checkpoints to induce the immune system into attacking cancer cells: https://kairospharma.com/about/

Kairos gets FDA clearance to begin Phase I trial of glioblastoma therapy - The trial of KROS 201 in recurrent glioblastoma patients will be initiated in Los Angeles.

Read more via GlobalData here: https://www.clinicaltrialsarena.com/news/kairos-trial-glioblastoma-therapy/

Kairos gets FDA clearance to begin Phase I trial of glioblastoma therapy The US FDA has granted clearance to Kairos Pharma’s IND application to commence Phase I trial of its KROS 201 for treating glioblastoma.

Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 of KROS 201 for the Treatment of ; Announces New Patent for KROS 401.

Read the news release here: https://prn.to/3KJFtdP

How are we using immune checkpoint �inhibitors to treat cancer?

Kairos Pharma is a clinical-stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.

https://kairospharma.com/pipeline/

We are seeking to transform the way cancer is treated by positively impacting patient outcomes while maintaining the quality of life.

Find out more: https://kairospharma.com/immunotherapy/

We are focused on a diversified pipeline of cutting-edge oncology therapeutics that reverse the inhibitory effects of cancer on the immune system.

Read more: https://kairospharma.com/

Kairos is developing an activated T-cell therapy that transforms a patient’s T cells into killer activated T cells against the stem cells that drive the patient’s cancer.

Read more: https://kairospharma.com/